Status:

RECRUITING

MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick

Lead Sponsor:

University of Massachusetts, Worcester

Collaborating Sponsors:

Massachusetts Institute of Technology

Breast Cancer Research Foundation

Conditions:

Breast Cancer

Eligibility:

FEMALE

40+ years

Phase:

NA

Brief Summary

Accurate risk assessment is essential for the success of population screening programs and early detection efforts in breast cancer. Mirai is a new deep learning model based on full resolution mammogr...

Eligibility Criteria

Inclusion

  • Women who were identified as high risk on the retrospective study (dating from 2017-2025) using MIRAI will be recruited and consented for the prospective study
  • Women over 40 years of age identified as high risk according to traditional guidelines will also be potentially eligible for this study
  • Following consent and enrollment in the study, a participant will subsequently receive the following:
  • These patients will be invited to receive a supplemental MRI examination currently considered the most sensitive test for breast cancer detection.
  • Any positive diagnosis on MRI will be followed by biopsy to confirm 'truth" of diagnosis.
  • To be selected, a given record must include the following:
  • A report of a routine screening mammogram or diagnostic mammogram, and availability of the DICOM images from that report with the PACS system.
  • Reports of all follow up screening and diagnostic studies documented on PACS.
  • Some may have interventional procedures (as long as all of these are done at one of Umass sites) and documentation of these biopsy results in the hospitals EHR.

Exclusion

  • Under age 40. Women under 40 years are not routinely xrayed with a mammogram.
  • Xray breast cancer screening imaging study that has artifacts, corruption, or other image quality degradation.
  • Pregnant patients because they do not routinely receive screening mammogram
  • Adult male patients with breast cancer

Key Trial Info

Start Date :

February 4 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2027

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT05968157

Start Date

February 4 2024

End Date

September 1 2027

Last Update

January 7 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UMass Medical School

Worcester, Massachusetts, United States, 01655